CINQCARE Teams with Humana to Provide In-Home Care

Our Bureau

CINQCARE, a company committed to deliver health and care where you live, with a deep commitment to Black and Brown communities, and leading health and well-being company Humana Inc. (NYSE: HUM), are teaming up to serve Medicare Advantage members throughout New York.

Together, the two companies, which share a dedication to comprehensive, whole-person health solutions, aim to improve healthcare challenges and close gaps in specific communities in the state.

“Our partnership with Humana represents a pivotal moment in our ongoing dedication to deliver care that treats members like family,” said Rodney Armstead, M.D., CINQCARE’s Chief Medical Officer. “Together, Humana and CINQCARE will work to create a positive and enduring impact on improving health, care and well-being in the homes and communities of those who need it most.”

CINQCARE, through its innovative “Care at Home” model, will offer robust care management to qualifying Humana members including around-the-clock telephonic nurse support and remote monitoring, and at-home services including visits from nurses and physicians.

“At Humana, our unwavering commitment has always been to provide high-quality care and improve health outcomes,” said Humana Northeast Regional Medicare President Julie Mascari. “By combining our expertise and resources, Humana and CINQCARE hope to make significant strides in improving the health and well-being of the diverse population of Medicare Advantage members we serve in New York.”


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505

Gilgamesh Pharmaceuticals, a clinical-stage neuroscience biotech developing best-in-class medicines to redefine mental healthcare, announces the successful completion of its Phase 1 Single Ascending Dose (SAD) trial of GM-2505, a novel 5-HT2A receptor agonist. While initially in development for treatment-resistant depression (TRD) and major depressive disorder (MDD), GM-2505 has the potential […]

Subscribe Now